CD133-targeted paclitaxel delivery inhibits local tumor recurrence in amousemodel of breast cancer

Journal of Controlled Release

Volumn 171, Issue 3, 2013, Pages 280-287

  Swaminathan, Suresh Kumar ^a   Roger, Emilie ^a   Toti, Udaya ^a   Niu, Lin ^a   Ohlfest, John R ^a,b   Panyam, Jayanth ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Department of Psychiatry   (United States)

Author keywords

Cancer initiating cells; Cancer stem cells; Polymeric nanoparticles; Sustained release; Targeted delivery

Indexed keywords

ANTIBODIES; CELLS; CONTROLLED DRUG DELIVERY; CYTOLOGY; DISEASES; DRUG THERAPY; MONOCLONAL ANTIBODIES; NANOPARTICLES; ORGANIC POLYMERS; POLYMERS; STEM CELLS;

ANTI-CANCER THERAPEUTICS; CANCER STEM CELLS; PACLITAXEL TREATMENT; POLY(D ,L-LACTIDE-CO- GLYCOLIDE); POLYMERIC NANOPARTICLES; SUSTAINED RELEASE; TARGETED DELIVERY; TARGETED NANOPARTICLE;

TUMORS;

CD133 ANTIGEN; CD133 MONOCLONAL ANTIBODY; COUMARIN; MONOCLONAL ANTIBODY; NANOCARRIER; PACLITAXEL; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER RECURRENCE; CANCER SIZE; CELL STRAIN CACO 2; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME; TUMOR INITIATING CELL;

CANCER INITIATING CELLS; CANCER STEM CELLS; POLYMERIC NANOPARTICLES; SUSTAINED RELEASE; TARGETED DELIVERY;

ANIMALS; ANTIBODIES, IMMOBILIZED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST; BREAST NEOPLASMS; CACO-2 CELLS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; GLYCOPROTEINS; HUMANS; MICE; MICE, INBRED BALB C; NANOPARTICLES; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PEPTIDES;

EID: 84892938139     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.07.014     Document Type: Article

References (64)

1. S.A. Narod, Breast cancer in young women, Nat. Rev. Clin. Oncol. 9 (2012) 460-470.
2. S. Germano, L. O'Driscoll, Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine, Curr. Cancer Drug Targets 9 (2009) 398-418.
3. C.E. Eyler, J.N. Rich, Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis, J. Clin. Oncol. 26 (2008) 2839-2845.
4. J.M. Chandler, E. Lagasse, Cancerous stem cells: deviant stem cells with cancercausing misbehavior, Stem Cell Res. Ther. 1 (2010) 13.
5. M. Al-Hajj, M.F. Clarke, Self-renewal and solid tumor stem cells, Oncogene 23 (2004) 7274-7282. (Pubitemid 39382161)
6. B.M. Boman, M.S. Wicha, Cancer stem cells: a step toward the cure, J. Clin. Oncol. 26 (2008) 2795-2799.
7. M. Dean, T. Fojo, S. Bates, Tumour stem cells and drug resistance, Nat. Rev. Cancer 5 (2005) 275-284. (Pubitemid 40488633)
8. S.E. Salmon, A.W. Hamburger, B. Soehnlen, B.G. Durie, D.S. Alberts, T.E. Moon, Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs, N. Engl. J. Med. 298 (1978) 1321-1327. (Pubitemid 8357629)
9. S. Bao, Q. Wu, R.E. McLendon, Y. Hao, Q. Shi, A.B. Hjelmeland, M.W. Dewhirst, D.D. Bigner, J.N. Rich, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature 444 (2006) 756-760. (Pubitemid 44949604)
10. K. Moitra, H. Lou, M. Dean, Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development, Clin. Pharmacol. Ther. 89 (2011) 491-502.
11. M. Diehn, R.W. Cho, N.A. Lobo, T. Kalisky, M.J. Dorie, A.N. Kulp, D. Qian, J.S. Lam, L.E. Ailles, M. Wong, B. Joshua, M.J. Kaplan, I. Wapnir, F.M. Dirbas, G. Somlo, C. Garberoglio, B. Paz, J. Shen, S.K. Lau, S.R. Quake, J.M. Brown, I.L. Weissman, M.F. Clarke, Association of reactive oxygen species levels and radioresistance in cancer stem cells, Nature 458 (2009) 780-783.
12. D. Trachootham, J. Alexandre, P. Huang, Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug Discov. 8 (2009) 579-591.
13. N. Moore, S. Lyle, Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance, J. Oncol. 2011 (2011).
14. A. Weigmann, D. Corbeil, A. Hellwig, W.B. Huttner, Prominin, a novel microvillispecific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 12425-12430. (Pubitemid 27492544)
15. A.H. Yin, S. Miraglia, E.D. Zanjani, G. Almeida-Porada, M. Ogawa, A.G. Leary, J. Olweus, J. Kearney, D.W. Buck, AC133, a novel marker for human hematopoietic stem and progenitor cells, Blood 90 (1997) 5002-5012. (Pubitemid 28007217)
16. N. Uchida, D.W. Buck, D. He, M.J. Reitsma, M. Masek, T.V. Phan, A.S. Tsukamoto, F.H. Gage, I.L. Weissman, Direct isolation of human central nervous system stem cells, Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14720-14725. (Pubitemid 32016642)
17. P. Brescia, B. Ortensi, L. Fornasari, D. Levi, G. Broggi, G. Pelicci, CD133 is essential for glioblastoma stem cell maintenance, Stem Cells 31 (2013) 857-869.
18. V. Catalano, S. Di Franco, F. Iovino, F. Dieli, G. Stassi, M. Todaro, CD133 as a target for colon cancer, Expert Opin. Ther. Targets 16 (2012) 259-267.
19. J. Miki, B. Furusato, H. Li, Y. Gu, H. Takahashi, S. Egawa, I.A. Sesterhenn, D.G. McLeod, S. Srivastava, J.S. Rhim, Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens, Cancer Res. 67 (2007) 3153-3161. (Pubitemid 46724852)
20. Y. Hori, Prominin-1 (CD133) reveals new faces of pancreatic progenitor cells and cancer stem cells: current knowledge and therapeutic perspectives, Adv. Exp. Med. Biol. 777 (2013) 185-196.
21. M.J. Meyer, J.M. Fleming, A.F. Lin, S.A. Hussnain, E. Ginsburg, B.K. Vonderhaar, CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptornegative breast cancer, Cancer Res. 70 (2010) 4624-4633.
22. D. Mizrak, M. Brittan, M. Alison, CD133: molecule of the moment, J. Pathol. 214 (2008) 3-9.
23. M.H. Wright, A.M. Calcagno, C.D. Salcido, M.D. Carlson, S.V. Ambudkar, L. Varticovski, Brca1 breast tumors contain distinct CD44+/CD24-and CD133+cells with cancer stem cell characteristics, Breast Cancer Res. 10 (2008) R10.
24. N. Aomatsu, M. Yashiro, S. Kashiwagi, T. Takashima, T. Ishikawa, M. Ohsawa, K. Wakasa, K. Hirakawa, CD133 is a useful surrogatemarker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer, PLoS One 7 (2012) e45865.
25. U.S. Toti, B.R. Guru, A.E. Grill, J. Panyam, Interfacial activity assisted surface functionalization: a novel approach to incorporate maleimide functional groups and cRGD peptide on polymeric nanoparticles for targeted drug delivery, Mol. Pharm. 7 (2010) 1108-1117.
26. Y.B. Patil, S.K. Swaminathan, T. Sadhukha, L. Ma, J. Panyam, The use of nanoparticlemediated targeted gene silencing and drug delivery to overcome tumor drug resistance, Biomaterials 31 (2010) 358-365.
27. E. Roger, S. Kalscheuer, A. Kirtane, B.R. Guru, A.E. Grill, J. Whittum-Hudson, J. Panyam, Folic acid functionalized nanoparticles for enhanced oral drug delivery, Mol. Pharm. 9 (2012) 2103-2110.
28. G. Dontu, W.M. Abdallah, J.M. Foley, K.W. Jackson, M.F. Clarke, M.J. Kawamura, M.S. Wicha, In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells, Genes Dev. 17 (2003) 1253-1270. (Pubitemid 36583168)
29. S.K. Swaminathan, M.R. Olin, C.L. Forster, K.S. Cruz, J. Panyam, J.R. Ohlfest, Identification of a novel monoclonal antibody recognizing CD133, J. Immunol. Methods 361 (2010) 110-115.
30. F.L. Shaw, H. Harrison, K. Spence, M.P. Ablett, B.M. Simoes, G. Farnie, R.B. Clarke, A detailed mammosphere assay protocol for the quantification of breast stem cell activity, J. Mammary Gland Biol. Neoplasia 17 (2012) 111-117.
31. D. Ponti, A. Costa, N. Zaffaroni, G. Pratesi, G. Petrangolini, D. Coradini, S. Pilotti, M.A. Pierotti, M.G. Daidone, Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties, Cancer Res. 65 (2005) 5506-5511. (Pubitemid 40911148)
32. T. Andrews, D. Wang, D. Harki, Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery, Drug Deliv. and Transl. Res. 3 (2013) 121-142.
33. M.V. Agrez, J.S. Kovach, M.M. Lieber, Cell aggregates in the soft agar "human tumour stem-cell assay", Br. J. Cancer 46 (1982) 880-887. (Pubitemid 13177694)
34. H. Clevers, The cancer stem cell: premises, promises and challenges, Nat. Med. 17 (2011) 313-319.
35. T. Lapidot, C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M.A. Caligiuri, J.E. Dick, A cell initiating human acutemyeloid leukaemia after transplantation into SCID mice, Nature 367 (1994) 645-648. (Pubitemid 24067706)
36. C. Li, D.G. Heidt, P. Dalerba, C.F. Burant, L. Zhang, V. Adsay, M. Wicha, M.F. Clarke, D.M. Simeone, Identification of pancreatic cancer stem cells, Cancer Res. 67 (2007) 1030-1037.
37. A.T. Collins, P.A. Berry, C. Hyde, M.J. Stower, N.J. Maitland, Prospective identification of tumorigenic prostate cancer stem cells, Cancer Res. 65 (2005) 10946-10951. (Pubitemid 41713363)
38. M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, M.F. Clarke, Prospective identification of tumorigenic breast cancer cells, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 3983-3988. (Pubitemid 36418143)
39. M. Florek, M. Haase, A.M. Marzesco, D. Freund, G. Ehninger, W.B. Huttner, D. Corbeil, Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer, Cell Tissue Res. 319 (2005) 15-26. (Pubitemid 40104635)
40. S.K. Singh, I.D. Clarke, M. Terasaki, V.E. Bonn, C. Hawkins, J. Squire, P.B. Dirks, Identification of a cancer stem cell in human brain tumors, Cancer Res. 63 (2003) 5821-5828. (Pubitemid 37187480)
41. G. Bertolini, L. Roz, P. Perego, M. Tortoreto, E. Fontanella, L. Gatti, G. Pratesi, A. Fabbri, F. Andriani, S. Tinelli, E. Roz, R. Caserini, S. Lo Vullo, T. Camerini, L. Mariani, D. Delia, E. Calabro, U. Pastorino, G. Sozzi, Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 16281-16286.
42. I.A. Silva, S. Bai, K. McLean, K. Yang, K. Griffith, D. Thomas, C. Ginestier, C. Johnston, A. Kueck, R.K. Reynolds, M.S. Wicha, R.J. Buckanovich, Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival, Cancer Res. 71 (2011) 3991-4001.
43. L.J. Harper, K. Piper, J. Common, F. Fortune, I.C. Mackenzie, Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma, J. Oral Pathol. Med. 36 (2007) 594-603. (Pubitemid 47609813)
44. C.A. O'Brien, A. Pollett, S. Gallinger, J.E. Dick, A human colon cancer cell capable of initiating tumour growth in immunodeficient mice, Nature 445 (2007) 106-110. (Pubitemid 46067310)
45. L. Ricci-Vitiani, D.G. Lombardi, E. Pilozzi, M. Biffoni, M. Todaro, C. Peschle, R. De Maria, Identification and expansion of human colon-cancer- initiating cells, Nature 445 (2007) 111-115. (Pubitemid 46067311)
46. S.K. Singh, C. Hawkins, I.D. Clarke, J.A. Squire, J. Bayani, T. Hide, R.M. Henkelman, M.D. Cusimano, P.B. Dirks, Identification of human brain tumour initiating cells, Nature 432 (2004) 396-401. (Pubitemid 39551674)
47. P. Zhao, Y. Lu, X. Jiang, X. Li, Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma, Cancer Sci. 102 (2011) 1107-1111.
48. R. Nadal, F.G. Ortega, M. Salido, J.A. Lorente, M. Rodriguez-Rivera, M. Delgado-Rodriguez, M. Macia, A. Fernandez, J.M. Corominas, J.L. Garcia-Puche, P. Sanchez-Rovira, F. Sole, M.J. Serrano, CD133 expression in circulating tumor cells frombreast cancer patients: potential role in resistance to chemotherapy, Int. J. Cancer (2013), http://dx.doi.org/10.1002/ijc.28263, (in press).
49. T.J. Liu, B.C. Sun, X.L. Zhao, X.M. Zhao, T. Sun, Q. Gu, Z. Yao, X.Y. Dong, N. Zhao, N. Liu, CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer, Oncogene 32 (2013) 544-553.
50. X.Y. Wang, L.O. Penalva, H. Yuan, R.I. Linnoila, J. Lu, H. Okano, R.I. Glazer, Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival, Mol. Cancer 9 (2010) 221.
51. T. Mine, S. Matsueda, Y. Li, H. Tokumitsu, H. Gao, C. Danes, K.K. Wong, X. Wang, S. Ferrone, C.G. Ioannides, Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells, Cancer Immunol. Immunother. 58 (2009) 1185-1194.
52. R. Zobalova, L. McDermott, M. Stantic, K. Prokopova, L.F. Dong, J. Neuzil, CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP, Biochem. Biophys. Res. Commun. 373 (2008) 567-571.
53. X. Li, M.T. Lewis, J. Huang, C. Gutierrez, C.K. Osborne, M.F. Wu, S.G. Hilsenbeck, A. Pavlick, X. Zhang, G.C. Chamness, H. Wong, J. Rosen, J.C. Chang, Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy, J. Natl. Cancer Inst. 100 (2008) 672-679.
54. C.J. Creighton, X. Li, M. Landis, J.M. Dixon, V.M. Neumeister, A. Sjolund, D.L. Rimm, H. Wong, A. Rodriguez, J.I. Herschkowitz, C. Fan, X. Zhang, X. He, A. Pavlick, M.C. Gutierrez, L. Renshaw, A.A. Larionov, D. Faratian, S.G. Hilsenbeck, C.M. Perou, M.T. Lewis, J.M. Rosen, J.C. Chang, Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features, Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 13820-13825.
55. V.S. Donnenberg, A.D. Donnenberg, Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis, J. Clin. Pharmacol. 45 (2005) 872-877. (Pubitemid 41060226)
56. J. Panyam, V. Labhasetwar, Biodegradable nanoparticles for drug and gene delivery to cells and tissue, Adv. Drug Deliv. Rev. 55 (2003) 329-347. (Pubitemid 36297053)
57. J. Ohlfest, D. Zellmer, J. Panyam, S. Swaminathan, S. Oh, N. Waldron, S. Toma, D. Vallera, Immunotoxin targeting CD133+ breast carcinoma cells, Drug Deliv. Transl. Res. 3 (2013) 195-204.
58. L.M. Smith, A. Nesterova, M.C. Ryan, S. Duniho, M. Jonas, M. Anderson, R.F. Zabinski, M.K. Sutherland, H.P. Gerber, K.L. Van Orden, P.A. Moore, S.M. Ruben, P.J. Carter, CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers, Br. J. Cancer 99 (2008) 100-109. (Pubitemid 351920235)
59. K. Kemper, M.R. Sprick, M. de Bree, A. Scopelliti, L. Vermeulen, M. Hoek, J. Zeilstra, S.T. Pals, H. Mehmet, G. Stassi, J.P. Medema, The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation, Cancer Res. 70 (2010) 719-729.
60. S. Bidlingmaier, X. Zhu, B. Liu, The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells, J. Mol. Med. 86 (2008) 1025-1032.
61. S. Swaminathan, L. Niu, N. Waldron, S. Kalscheuer, D. Zellmer, M. Olin, J. Ohlfest, D. Vallera, J. Panyam, Identification and characterization of a novel scFv recognizing human and mouse CD133, Drug Deliv. Transl. Res. 3 (2013) 143-151.
62. N.N. Waldron, D.S. Kaufman, S. Oh, Z. Inde, M.K. Hexum, J.R. Ohlfest, D.A. Vallera, Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer, Mol. Cancer Ther. 10 (2011) 1829-1838.
63. M. Damek-Poprawa, A. Volgina, J. Korostoff, T.P. Sollecito, M.S. Brose, B.W. O'Malley Jr., S.O. Akintoye, J.M. DiRienzo, Targeted inhibition of CD133+ cells in oral cancer cell lines, J. Dent. Res. 90 (2011) 638-645.
64. P.B. Gupta, T.T. Onder, G. Jiang, K. Tao, C. Kuperwasser, R.A. Weinberg, E.S. Lander, Identification of selective inhibitors of cancer stemcells by high-throughput screening, Cell 138 (2009) 645-659.